Search research articles
Contact Us
Filters
Showing results (51-60 of 101) with videos related to
Page
of 11
Sort By:
BMC Urology
|
July 4, 2020
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations
Yasser Ged, Ruby Gupta, Cihan Duzgol, et al.
European Urology
|
November 7, 2022
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
Kelly N Fitzgerald, Cihan Duzgol, Andrea Knezevic, et al.
Clinical Genitourinary Cancer
|
December 1, 2024
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials
Sahil D Doshi, Andrea Knezevic, Carlene Gonzalez, et al.
Clinical Genitourinary Cancer
|
June 2, 2019
Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes
Yasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Clinical Genitourinary Cancer
|
May 1, 2019
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes
Yasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
The Journal of Clinical Investigation
|
August 3, 2016
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
Jianing Xu, Can G Pham, Steven K Albanese, et al.
The Oncologist
|
May 11, 2025
Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors
Ian Nykaza, Yonina R Murciano-Goroff, Antoine Desilets, et al.
Clinical Genitourinary Cancer
|
June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes
Maria I Carlo, Joshua Chaim, Sujata Patil, et al.
Cancer Medicine
|
December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
Michal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
JCO Precision Oncology
|
February 17, 2022
Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i>-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect
Chung-Han Lee, Gunes Gundem, William Lee, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 101) with videos related to
Sort By:
Page
of 11
BMC Urology
|
July 4, 2020
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations
Yasser Ged, Ruby Gupta, Cihan Duzgol, et al.
European Urology
|
November 7, 2022
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
Kelly N Fitzgerald, Cihan Duzgol, Andrea Knezevic, et al.
Clinical Genitourinary Cancer
|
December 1, 2024
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials
Sahil D Doshi, Andrea Knezevic, Carlene Gonzalez, et al.
Clinical Genitourinary Cancer
|
June 2, 2019
Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes
Yasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Clinical Genitourinary Cancer
|
May 1, 2019
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes
Yasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
The Journal of Clinical Investigation
|
August 3, 2016
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
Jianing Xu, Can G Pham, Steven K Albanese, et al.
The Oncologist
|
May 11, 2025
Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors
Ian Nykaza, Yonina R Murciano-Goroff, Antoine Desilets, et al.
Clinical Genitourinary Cancer
|
June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes
Maria I Carlo, Joshua Chaim, Sujata Patil, et al.
Cancer Medicine
|
December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
Michal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
JCO Precision Oncology
|
February 17, 2022
Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i>-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect
Chung-Han Lee, Gunes Gundem, William Lee, et al.
Page
of 11